Highly active compounds against COVID-19
US11813278B2 · kind B2 · utility
1Cited by
199References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 24, 2021 |
| Grant date | Nov 14, 2023 |
| Priority date | — |
| Expiry date | Feb 24, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/207
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.